

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 1 of 3

*Complete if Known*

<b>Application Number</b>	10/595,999
<b>Filing Date</b>	May 24, 2006
<b>First Inventor</b>	Walzer et al.
<b>Art Unit</b>	TBA
<b>Examiner Name</b>	TBA
<b>Attorney Docket No.</b>	91830.0542088

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	<u>Document Number</u> Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant	Pages, columns, lines where relevant passages or relevant figures appear
		US 2005/0113424	05-26-2005	Hayashi, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	<u>Foreign Patent Document</u> Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant	Pages, columns, lines where relevant passages or relevant figures appear	T <sup>6</sup>
		WO 2005/033065	04-14-2005	Tidwell et al.		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		VANDEN EYNDE JEAN JACQUES ET AL: "Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 6 SEP 2004, vol. 14, no. 17, 6 September 2004 (2004-09-06), pages 4545-4548, XP002374421 ISSN: 0960-894X	
		TAO BIN ET AL: "Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 6, June 1999 (1999-06), pages 531-538, XP002374422 ISSN: 0223-5234	
		HUANG TIEN L ET AL: "N,N'-Bis(4-(N-alkylamidino)phenyl)homopiperazines as anti-Pneumocystis carinii agents" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 20, 22 October 2001 (2001-10-22), pages 2679-2681, XP002374423 ISSN: 0960-894X	
		HUANG TIEN L ET AL: "Synthesis and anti-Pneumocystis carinii activity of piperidine-linked aromatic diimidazolines" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 17, 1996, pages 2087-2090, XP002374424 ISSN: 0960-894X	
		BOYKIN D W ET AL: "Dicationic diarylfurans as anti-Pneumocystis carinii agents." JOURNAL OF MEDICINAL CHEMISTRY. 17 MAR 1995, vol. 38, no. 6, 17 March 1995 (1995-03-17), pages 912-916, XP002374425 ISSN: 0022-2623.	
		BOYKIN D W ET AL: "2,5-bis[4-N-alkylamidino)phenyl]furans as anti-Pneumocystis carinii agents." JOURNAL OF MEDICINAL CHEMISTRY. 1 JAN 1998, vol. 41, no. 1, 1 January 1998 (1998-01-01), pages 124-129, XP002374426 ISSN: 0022-2623.	
		FRANCESCONI I ET AL: "2,4-Diphenyl furan diamidines as novel anti-Pneumocystis carinii pneumonia agents." JOURNAL OF MEDICINAL CHEMISTRY. 17 JUN 1999 (1999-06-17), pages 2260-2265, XP002374427 ISSN: 0022-2623.	

Examiner  
SignatureDate  
Considered

Substitute for Form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 3

Complete if Known

Application Number	10/595,999
Filing Date	May 24, 2006
First Inventor	Walzer et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket No.	91830.0542088

		MAYENCE ANNIE ET AL: "Parallel solution-phase synthesis of conformationally restricted congeners of pentamidine and evaluation of their antiparasmodial activities." JOURNAL OF MEDICINAL CHEMISTRY. 6 MAY 2004, vol. 47, no. 10, 6 May 2004 (2004-05-06), pages 2700-2705, XP002374428 ISSN: 0022-2623.	
		Beard, C. B., Carter, J. L., Keely, S. P., Huang, L., Pieniazek, N. J., Moura, I. N., Roberts, J. M., Hightower, A. W., Bens, M. S., Freeman, A. R., Lee, S., Stringer, J. R., Duchin, J. S., del Rio, C., Rimland, D., Baughman, R. P., Levy, D. A., Dietz, V. J., Simon, P., and Navin, T. R., Genetic variation in <i>Pneumocystis carinii</i> isolates from different geographic regions: implications for transmission. <i>Emerg.Infect.Dis.</i> 2000.May-Jun.:6,(3.):265-72, 6, 265-272.	
		Castro, M. (1998). Treatment and prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Semin.Respir.Infect.</i> 13. 296-303.	
		Centers for Disease Control and Prevention (1999). Surveillance for AIDS-defining opportunistic illnesses 1993-1997. <i>MMWR.Morb.Mortal.Wkly.Rep.</i> 48 No. SS-2.	
		Chen, F. and Cushion, M. T. (1994). Use of an ATP bioluminescent assay to evaluate viability of <i>Pneumocystis carinii</i> from rats. <i>J.Clin.Microbiol.</i> 32, 2791-2800.	
		Collins, M. S. and Cushion, M. T. (2001). Standardization of an in vitro drug screening assay by use of cryopreserved and characterized <i>Pneumocystis carinii</i> populations. <i>J.Eukaryot.Microbiol. Supp.</i> 178S-179S., 178S-179S.	
		Cushion, M. T., Chen, F., and Kloepper, N. (1997). A cytotoxicity assay for evaluation of candidate anti- <i>Pneumocystis carinii</i> agents, <i>Antimicrob.Agents Chemother.</i> 41, 379-384.	
		Cushion, M. T., Collins, M., Hazra, B., and Kaneshiro, E. S. (2000). Effects of atovaquone and diospyrin-based drugs on the cellular ATP of <i>Pneumocystis carinii</i> f. sp. <i>carinii</i> . <i>Antimicrob.Agents Chemother.</i> 44, 713-719.	
		Cushion, M. T., Ruffolo, J. J., Linke, M. J., and Walzer, P. D. (1985). <i>Pneumocystis carinii</i> : growth vegetables and estimates in the A549 and WI-38 VA13 human cell lines. <i>Exp.Parasitol.</i> 60, 43-54.	
		Cushion, M. T., Stanforth, D., Linke, M. J., and Walzer, P. D. (1985). Method of testing the susceptibility of <i>Pneumocystis carinii</i> to antimicrobial agents in vitro. <i>Antimicrob.Agents Chemother.</i> 28, 796-801.	
		Cushion, M. T., and Walzer, P. D. (1984a). Cultivation of <i>Pneumocystis carinii</i> in lung-derived cell lines. <i>J.Infect.Dis.</i> 149, 644.	
		Cushion, M. T., and Walzer, P. D. (1984b). Growth and serial passage of <i>Pneumocystis carinii</i> in the A549 cell line. <i>Infect.Immun.</i> 44, 245-251.	
		Frenkel, J. K., Good, J. T., and Shultz, J. A. (1966). Latent <i>Pneumocystis</i> infection of rats, relapse, and chemotherapy. <i>Lab.Invest.</i> 15, 1559-1577.	
		Hughes, W. T., Gray, V. L., Gutteridge, W. E., Latter, V. S., and Pudney, M. (1990). Efficacy of a hydroxynaphthoquinone, 566C80, in experimental <i>Pneumocystis carinii</i> pneumonitis. <i>Antimicrob.Agents Chemother.</i> 34, 225-228.	
		Kaneshiro, E. S., Collins, M., and Cushion, M. T. (1999). Effects of sterol inhibitors on the ATP content of <i>Pneumocystis carinii</i> , <i>J.Eukaryot.Microbiol.</i> 45, 142S-143S.	
		Kazanjan, P., Armstrong, W., Hossler, P. A., Burman, W., Richardson, J., Lee, C. H., Crane, L., Katz, J., and Meshnick, S. R., <i>Pneumocystis carinii</i> mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. <i>J.Infect.Dis.</i> 2000.Aug.:182,(2.):551.-7. 182, 551-557.	

Examiner Signature

Date  
Considered

Substitute for Form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 3

Complete if Known

Application Number	10/595,999
Filing Date	May 24, 2006
First Inventor	Walzer et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket No.	91830.0542088

		Kazanjian, P., Armstrong, W., Hossler, P. A., Lee, C. H., Huang, L., Beard, C. B., Carter, J., Crane, L., Dutchin, J., Burman, W., Richardson, J., and Meshnick, S. R., Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. <i>J.Infect.Dis.</i> 2001 <i>Mar. 1.</i> :183(5.):819-22. 183, 819-822.	
		Ma, L., Borio, L., Masur, H., and Kovacs, J. A. (1999). Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. <i>J.Infect.Dis.</i> 180, 1969-1978.	
		Mei, Q., Gurunathan, S., Masur, H., and Kovacs, J. A. (1998). Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. <i>Lancet</i> 351, 1631-1632.	
		Mills, J., Leoung, G., Medina, I., Hopewell, P. C., Hughes, W. T., and Wofsy, C. (1988) Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. <i>Antimicrob.Agents Chemother.</i> 32, 1057-1060.	
		Walker, D. J., Wakefield, A. E., Dohn, M. N., Miller, R. F., Baughman, R. P., Hossler, P. A., Barlett, M. S. Smith, J. W., Kazanjian, P., and Meshnick, S. R. (1998). Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. <i>J.Infect.Dis.</i> 178, 1767-1775.	
		Walzer, P. D. (1991). Overview of animal models of Pneumocystis carinii pneumonia. <i>J.Protozool.</i> 38, 122S-123S.	
		Walzer, P. D., Ashbaugh, A., Collins, M., and Cushion, M. T. (2001), In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii. <i>Antimicrob.Agents Chemother.</i> 45, 3234-3237.	
		Walzer, P. D., Foy, J., Runck, J., Steele, P., White, M., Klein, R. S., Otter, B. A., and Sundberg, R. J. (1994). Guanyldihydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats. <i>Antimicrob.Agents Chemother.</i> 38, 2572-2576.	
		Walzer, P. D., Foy, J., Steele, P., Kim, C. K., White, M., Klein, R. S., Otter, B. A., and Allegra, C. (1992a). Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. <i>Antimicrob.Agents Chemother.</i> 36, 1935-1942.	
		Walzer, P. D., Foy, J., Steele, P., and White, M. (1992b). Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. <i>Antimicrob.Agents Chemother.</i> 36, 1943-1950.	
		Walzer, P. D., Runck, J., Orr, S., Foy, J., Steele, P., and White, M., (1997). Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. <i>Antimicrob.Agents Chemother.</i> 41, 242-250.	
		Wilkin, A. and Feinberg, J. (1999). Pneumocystis carinii pneumonia: a clinical review. <i>Am.Fam.Physician.</i> 60, 1699-4.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.